Spruce Biosciences, Inc.

NASDAQ:SPRB

Biotechnology

Healthcare
$40.84 +5.07%

+$2.47 today

Market cap
$117.37M
Beta
3.20
P/E (TTM)
-1.9
EPS (TTM)
-$27.11
52W Low $7.00High $838.13

Volume 0.06M

Average 0.06M

SPRB Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Spruce Biosciences, Inc.NASDAQ: SPRB

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization growth accelerates

Q1 FY2026 depreciation & amortization of $252K rose 4100.0% year over year, ahead of the +621.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 4940.0% from the prior quarter. Over 3 fiscal years it compounded at -34.3% a year.

Context

  • Depreciation & amortization increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +4100.0% holds above the trailing-twelve-month pace of +621.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$252K+4940.0% QoQ
Last fiscal yearDec 2025
$21K-54.3% YoY
LTMMar 2026
$267K+621.6% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4100.0%——
1 year-54.3%——
3-year CAGR-34.3%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
21K USD
Year-over-year change
-54.3%
4-year CAGR
-25.5%

Depreciation & Amortization vs competitors

How SPRB compares with its peers on the latest reported figures

  • SPRB's LTM Mar 2026 depreciation & amortization of $267K is the 6th highest of the 9 companies compared; the peer median is $396.66K.
  • Its year-over-year change of +621.6% is the 2nd highest of 9, against a peer median of +8.6%.
  • Over three fiscal years its annual growth of -34.3% compares with a peer median of +10.4%.
SPRB Competitors Peer median
Depreciation & Amortization for SPRB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HOWLWerewolf Therapeutics, Inc.LTM Jun 2026$3.65M +111.3%+14.0%17.4%
CUECue Biopharma, Inc.LTM Mar 2026$3.01M +10.5%+24.4%9.2%
COEPCoeptis Therapeutics, Inc.LTM Mar 2026$1.17M +6.7%+6.9%82.6%
OSTXOS Therapies IncorporatedLTM Mar 2026$487.33K +42.9%+666.9%—
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$306K +6020.0%+229.4%13.3%
SPRBSpruce Biosciences, Inc.LTM Mar 2026$267K +621.6%-34.3%—
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$119.64K +3.7%-17.0%35.9%
EQEquillium, Inc.LTM Mar 2026$107K -22.5%-0.6%—
VTVTvTv Therapeutics Inc.LTM Mar 2026$8K -89.5%-44.2%0.0%
Peer median (excluding SPRB) $396.66K+8.6%+10.4%15.4%

Competitors are the stored peer set for SPRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0010.09M4.91M0
Cost of Revenue00000
Gross Profit0010.09M4.91M0
Gross Margin——100.0%100.0%—
Research & Development30.7M35.2M49.43M46.42M19.52M
Selling, General & Admin11.37M12.09M12.65M14.64M16.99M
Operating Expenses42.07M47.28M62.08M61.06M36.51M
Depreciation & Amortization68K74K70K46K21K
EBITDA(41.88M)(45.69M)(47.37M)(52.68M)(38.86M)
EBITDA Margin——-469.5%-1072.8%—
Operating Income(42.07M)(47.28M)(51.99M)(56.15M)(36.51M)
Operating Margin——-515.3%-1143.4%—
Interest Income119K1.52M4.56M3.42M1.14M
Interest Expense345K420K483K307K90K
Other Income / Expenses(226K)1.1M4.07M3.12M(2.45M)
Income Before Tax(42.29M)(46.18M)(47.92M)(53.04M)(38.97M)
Pre-Tax Margin——-475.0%-1079.9%—
Income Tax Expense00000
Net Income(42.29M)(46.18M)(47.92M)(53.04M)(38.97M)
Net Margin——-475.0%-1079.9%—
EPS (Basic)(68.25)(72.00)(93.00)(96.75)(50.83)
EPS (Diluted)(68.25)(72.00)(93.00)(96.75)(50.83)
Weighted Avg Shares607.4K611.71K500.63K536.44K766.6K
Weighted Avg Shares (Diluted)607.4K611.71K500.63K536.44K766.6K

Spruce Biosciences, Inc.

NASDAQ:SPRB

Intrinsic Alpha fair value

Locked

Current Price

$40.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.